Edition:
United States

Immunotec Inc (IMM.V)

IMM.V on TSX Venture Exchange

0.47CAD
--
Change (% chg)

-- (--)
Prev Close
$0.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
33,210
52-wk High
$0.49
52-wk Low
$0.29

Latest Key Developments (Source: Significant Developments)

Immunotec reports qtrly revenues C$30.8 million
Monday, 27 Mar 2017 06:21pm EDT 

Immunotec Inc : Immunotec reports first quarter results . Q1 earnings per share C$0.01 .Qtrly revenues C$30.8 million versus. C$22.9 million.  Full Article

Immunotec enters into agreement to be acquired
Wednesday, 22 Mar 2017 04:26pm EDT 

Immunotec Inc : Immunotec Inc - Deal for a cash consideration of $0.485 per share . Immunotec enters into agreement to be acquired . Says transaction has been unanimously approved by board of directors of Immunotec . Immunotec Inc- Immuno Holding is expected to acquire all of issued and outstanding common shares of company .Immunotec Inc - Termination fee of $2 million is payable to Immuno Holding in certain circumstances.  Full Article

Immunotec reports Q4 earnings per share C$0.01
Thursday, 26 Jan 2017 04:50pm EST 

Immunotec Inc - : Immunotec reports fourth quarter and full-year 2016 results . Q4 earnings per share C$0.01 ."Annual revenues surpassed our expectations and reached an all-time high of $109 million".  Full Article

Immunotec Inc posts qtrly rev C$25.6 mln vs C$20 mln last year
Thursday, 16 Jun 2016 04:17pm EDT 

Immunotec Inc : Immunotec reports second quarter results .Immunotec Inc qtrly revenues C$25.6 million versus C$20.00 million last year.  Full Article

Immunotec Inc renews material contract with glanbia nutritionals
Friday, 8 Apr 2016 04:05pm EDT 

Immunotec Inc:Renewal, for a five (5) year period, of its Supply and Manufacturing Agreement with Glanbia Nutritionals ("Glanbia").Says new contract replaces the previous agreement signed in May 2011.  Full Article

More From Around the Web

BRIEF-Immunotec reports qtrly revenues C$30.8 million

* Qtrly revenues C$30.8 million versus. C$22.9 million Source text for Eikon: Further company coverage:

No consensus analysis data available.